Neumora Therapeutics (NMRA) Net Cash Flow (2022 - 2026)

Neumora Therapeutics has reported Net Cash Flow for 5 years, with the latest figure at -$35.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 131.93% year-over-year to -$35.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.0 million (up 133.89% YoY), and the FY2025 full-year result was $39.2 million, up 116.89% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$35.5 million, down from $53.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $208.1 million in Q3 2023, with the low at -$191.1 million in Q1 2024.
• Average Net Cash Flow over 5 years is -$7.6 million, with a median of -$13.4 million recorded in 2022.
• Year-over-year, Net Cash Flow sank 534.44% in 2024 and soared 140.02% in 2025.
• Tracing NMRA's Net Cash Flow over 5 years: stood at -$11.6 million in 2022, then slumped by 230.76% to -$38.2 million in 2023, then sank by 249.23% to -$133.6 million in 2024, then soared by 140.02% to $53.5 million in 2025, then plunged by 166.33% to -$35.5 million in 2026.
• The last three Net Cash Flow figures came in at -$35.5 million (Q1 2026), $53.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.

Peer Comparison